Hemoblastoses represent two broad groups of bone marrow and extramedullary malignant blood pathologies, the common signs of which include the development of hematopoietic function disorders, immunodeficiency, anemia, and hemorrhagic syndrome in the patient. Treatment of hemoblastoses in Israel is conducted by oncologists-hematologists who are respected in the international medical community and possess extensive clinical experience in addressing issues of operational diagnostics and building effective therapy schemes. The innovative methods of targeted therapy, adaptive CAR-T cell therapy, and the latest low-toxicity chemotherapy drugs allow for achieving stable remission in most cases, and in some types of hemoblastoses, complete recovery of the patient.
Early treatment significantly improves prognosis, allows for symptom relief, and greatly enhances the quality of life for the patient. The modern high-precision equipment of Israeli clinics, along with advanced methodologies for instrumental and laboratory research, ensures the prompt establishment of an accurate diagnosis and the selection of the most effective treatment methods and medications for the patient. Patient reviews confirm noticeable improvement soon after the start of treatment, highlighting the reasonable cost of services and a high level of comfort.
Treatment Methods for Diseases
Hemoblastoses are a primary malignant pathology of the hematopoietic and lymphatic tissues. In recent years, the incidence of hemoblastoses has been steadily increasing worldwide, currently ranking fifth among all types of oncological diseases. According to statistical studies, this pathology is more common in men, with rural populations being less affected than urban residents.
Hemoblastoses are divided into two large groups:
- leukemias — oncological diseases of hematopoietic tissue characterized by bone marrow involvement;
- hematosarcomas (lymphomas) — extramedullary tumours, most often developing in lymph nodes.
As the disease progresses, various forms of hemoblastoses can transform into one another. For instance, in the development of leukemias, malignant cells may spread to lymph nodes, while in hematosarcomas, involvement of the bone marrow occurs, leading to changes in the blood picture characteristic of leukemia. Acute and chronic forms of leukemia are distinguished, while hematosarcomas include Hodgkin's lymphoma and non-Hodgkin lymphomas.
Numerous studies have not identified the exact causes of hemoblastoses. However, it is known that the risk of developing the pathology significantly increases with exposure to ionizing and ultraviolet radiation, including undergoing courses of radiotherapy and radiological diagnostic procedures. Chemical carcinogens that stimulate the onset of hemoblastoses include compounds such as benzene and certain medications. The likelihood of developing the disease increases in cases of conditions based on genetic and chromosomal mutations, viral infections, and metabolic disorders.
The symptoms of hemoblastoses are quite diverse, with typical signs including hemorrhagic syndrome, anemia, increased fatigue, weakness, and sweating. Patients often experience nasal and intestinal bleeding, as well as bleeding gums. As a result of the formation of an immunodeficient state, patients have reduced resistance to infectious diseases, with infections developing rapidly and severely.
Israeli oncologists-hematologists use modern treatment methods for hemoblastoses tailored based on the patient's diagnostic examination data. When developing a therapy program, the presence of genetic mutations, the stage of the disease, and the overall condition of the patient are taken into account.
Chemotherapy
To eliminate the maximum number of malignant cells, the first stage of treatment includes high-dose polychemotherapy. Chemotherapy drugs are most often administered intravenously, although intrathecal (into the spinal canal) administration is also possible. Upon achieving stable remission, the patient is prescribed maintenance chemotherapy courses, during which low doses of chemotherapy drugs are administered.
Radiotherapy
External radiation of the malignant focus prevents the chaotic division of cancer cells, helps alleviate pain syndrome, and reduces swelling. In neuroleukemia, ionizing radiation affects the brain structures responsible for the production of cerebrospinal fluid, as well as certain areas of the cervical spine. In Israel, radiotherapy sessions are performed on modern equipment that allows for precise irradiation of the tumour surface while minimally affecting normal tissues.
Targeted Therapy
The principle of action of targeted drugs used for the treatment of hemoblastoses lies in the accurate recognition and suppression of the synthesis and activity of oncogenic enzymes. As a result, the necessary metabolic processes are blocked exclusively in cancer cells. Gradually, the population of tumour cells dies off, while the unaltered ones recover. Targeted therapy does not cause side effects, making it recommended for weakened patients.
CAR-T Therapy
An innovative immunotherapy method recently introduced into the practice of treating hemoblastoses. The technique is based on developing the ability of the patient's T-lymphocytes to rapidly recognize the cells of this tumour. Modifications of the patient's T-lymphocytes are carried out using genetic engineering laboratory techniques. Since CAR-T therapy is associated with the development of side effects, it is not prescribed for weakened elderly patients. However, its application in children ensures stable remission in more than 92% of cases.
Bone Marrow Transplantation
The procedure is conducted in two stages. Initially, the patient is prescribed high-dose chemotherapy, leading to complete suppression of the hematopoietic system, after which either autologous (autotransplantation) or donor (allotransplantation) bone marrow transplantation is performed.
Surgical Treatment
Typically included in the symptomatic therapy program for lymphomas. Surgical intervention is indicated in cases where lymphoid tissue compresses major blood vessels, nerves, or internal organs.
Supportive Therapy
Symptomatic medication treatment is conducted using the following drugs:
- antibiotics;
- steroid hormones;
- antiemetics;
- metabolic drugs;
- vitamin-mineral complexes.
Diagnostic Methods for Diseases
In Israeli clinics, patient examination and treatment scheme development takes about three days.
Upon admission to the clinic, the patient visits a leading oncologist-hematologist. During the consultation, the doctor reviews the medical history and the results of previous studies, conducts a physical examination, and compiles a list of necessary examinations.
On the following day, the types of diagnostic procedures listed in the appointments are performed:
- complete blood count;
- detection of specific tumor markers in the blood;
- molecular genetic tests;
- bone marrow biopsy;
- imaging studies (X-ray, CT, MRI, PET-CT);
- ultrasound examination;
- scintigraphy.
The results of the studies are reviewed by a medical council consisting of an oncologist-hematologist and specialized experts. The doctors collectively establish the final diagnosis and prescribe treatment.
How Much Does Treatment Cost
Most patients are interested in the price of the treatment course and its affordability for them. Undergoing treatment in Israeli clinics provides savings of about 30% compared to Western European countries and is approximately 50% cheaper than in the USA.
Advantages of Treatment in Israel
- Effectiveness of anti-tumour therapy.
- Qualification and experience of doctors.
- Modern material and technical base.
- Use of progressive therapeutic and diagnostic methods.
- Affordable prices.
Modern achievements in medicine and pharmacology allow us to view hemoblastoses not as a death sentence, but as a serious disease requiring timely and comprehensive therapy. Don't waste time, contact your chosen Israeli clinic and start treatment as soon as possible.